Safety Profile
Known Safety Concerns
- Maple syrup urine disease (MSUD) -- absolute contraindication
- High doses may affect tryptophan/serotonin metabolism
- High protein intake caution in renal disease
Contraindications
- Maple syrup urine disease (MSUD) -- absolute contraindication
- High doses may affect tryptophan/serotonin metabolism
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
L-valine is a branched-chain essential amino acid important for protein synthesis and energy metabolism in muscle. Well-tolerated at supplemental doses. Maple syrup urine disease (MSUD) is a contraindication.
Biological and Chemical Classification
- Scientific Name
- L-Valine (2-amino-3-methylbutanoic acid)
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Metabolic
- Evidence consistency: High consistency across studies (100%)
- Maple syrup urine disease (MSUD) -- absolute contraindication
- High doses may affect tryptophan/serotonin metabolism
- High protein intake caution in renal disease
The available scientific evidence for L-Valine indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 25 მარ 2026, 22:50
Evidence Distribution
-
Observational / other LOW evidence YELLOWIntegrating metabolomics and metagenomics reveals potential mechanism of rice root exudates in inhibiting nitrification in coastal saline soils. ↗Jiang J et al.. Integrating metabolomics and metagenomics reveals potential mechanism of rice root exudates in inhibiting nitrification in coastal saline soils.. Environ Res. 2026. PMID:41819201.PMID 41819201 ↗Journal Environ ResYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41819201/
-
Observational / other LOW evidence YELLOW[UHPLC-Orbitrap-MS and targeted metabolomics reveal chemical distribution characteristics and main chemical content of Tibetan medicine Liuwei Muxiang Pills]. ↗Duo JJ et al.. [UHPLC-Orbitrap-MS and targeted metabolomics reveal chemical distribution characteristics and main chemical content of Tibetan medicine Liuwei Muxiang Pills].. Zhongguo Zhong Yao Za Zhi. 2026. PMID:41814839.PMID 41814839 ↗Journal Zhongguo Zhong Yao Za ZhiYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41814839/
-
Observational / other LOW evidence YELLOWEffect of solid-state fermentation on protein content, amino acid digestibility and anti-nutritional components of common beans, lentils and chickpeas. ↗Lux A et al.. Effect of solid-state fermentation on protein content, amino acid digestibility and anti-nutritional components of common beans, lentils and chickpeas.. Food Res Int. 2026. PMID:41794452.PMID 41794452 ↗Journal Food Res IntYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41794452/
-
Observational / other LOW evidence YELLOWPrecursor balancing by reprogramming pyruvate synthesis for high-yield l-isoleucine production in engineered Escherichia coli. ↗Huo X et al.. Precursor balancing by reprogramming pyruvate synthesis for high-yield l-isoleucine production in engineered Escherichia coli.. Bioresour Technol. 2026. PMID:41740936.PMID 41740936 ↗Journal Bioresour TechnolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41740936/
-
Observational / other LOW evidence YELLOWMultistep metabolic engineered Klebsiella oxytoca for efficient l-leucine production. ↗Sun W et al.. Multistep metabolic engineered Klebsiella oxytoca for efficient l-leucine production.. Synth Syst Biotechnol. 2026. PMID:41704463.PMID 41704463 ↗Journal Synth Syst BiotechnolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41704463/
-
Observational / other LOW evidence YELLOWLactobacillus plantarum (LPsca12) enhances growth phenotype and muscle nutrition in abalone (Haliotis discus hannai) by modulating microbial function and metabolism through the… ↗He Y et al.. Lactobacillus plantarum (LPsca12) enhances growth phenotype and muscle nutrition in abalone (Haliotis discus hannai) by modulating microbial function and metabolism through the Amino Acid-Driven Gut-Muscle Axis.. Anim Microbiome. 2026. PMID:41634812.PMID 41634812 ↗Journal Anim MicrobiomeYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41634812/
-
Observational / other LOW evidence YELLOWEnhancing Spore Inactivation: Low-Intensity Pulsed Electric Field Combined with Ohmic Heating and Germinant Pretreatment. ↗Xu FY et al.. Enhancing Spore Inactivation: Low-Intensity Pulsed Electric Field Combined with Ohmic Heating and Germinant Pretreatment.. Foods. 2026. PMID:41596829.PMID 41596829 ↗Journal FoodsYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41596829/
-
Observational / other LOW evidence YELLOWChloracidobacterium validum sp. nov., a thermophilic chlorophotoheterotrophic bacterium of the phylum Acidobacteriota from an alkaline hot spring microbial mat, represents Chloracidobacterium gen.… ↗Saini MK et al.. Chloracidobacterium validum sp. nov., a thermophilic chlorophotoheterotrophic bacterium of the phylum Acidobacteriota from an alkaline hot spring microbial mat, represents Chloracidobacterium gen. nov., Chloracidobacteriaceae fam. nov. and Chloracidobacteriales ord. nov.. Int J Syst Evol Microbiol. 2026. PMID:41553838.PMID 41553838 ↗Journal Int J Syst Evol MicrobiolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41553838/
-
Observational / other LOW evidence YELLOWEnhanced Longevity and Immunity in Caenorhabditis elegans through Ingestion of Lactiplantibacillus plantarum SKO-001: A Multi-Omics Study. ↗Lee DJ et al.. Enhanced Longevity and Immunity in Caenorhabditis elegans through Ingestion of Lactiplantibacillus plantarum SKO-001: A Multi-Omics Study.. Food Sci Anim Resour. 2025. PMID:41821702.PMID 41821702 ↗Journal Food Sci Anim ResourYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41821702/
-
Observational / other LOW evidence YELLOWl-Valine ethyl ester hydro-chloride. ↗Van Rooyen E et al.. l-Valine ethyl ester hydro-chloride.. IUCrdata. 2025. PMID:41551121.PMID 41551121 ↗Journal IUCrdataYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41551121/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for L-Valine. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for L-Valine
A score of 2.0 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.